Rohan's questions to Sarepta Therapeutics Inc (SRPT) leadership • Q3 2024
Question
Rohan, on for Mike Ulz at Morgan Stanley, asked for color on early Q4 trends for ELEVIDYS sales and how they are tracking against the company's expectations.
Answer
President and CEO Doug Ingram declined to provide intra-quarter commentary. He reiterated the company's existing guidance for Q4 and its full-year 2025 forecast of $3 billion in total revenue, stating that performance is tracking consistently with internal forecasts and that the company feels very good about its position.